Unknown

Dataset Information

0

Desquamative extravasation reaction secondary to enfortumab vedotin.

ABSTRACT:

SUBMITTER: Pulavarty AN 

PROVIDER: S-EPMC10943994 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Desquamative extravasation reaction secondary to enfortumab vedotin.

Pulavarty Akshay N AN   Meehan Shane S   Weed Jason J  

JAAD case reports 20240213

Similar Datasets

Unknown Drug extravasation with Enfortumab vedotin.
| S-EPMC10612376 | biostudies-literature
Unknown Enfortumab Vedotin in urothelial cancer.
| S-EPMC7780177 | biostudies-literature
Unknown Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin.
| S-EPMC7863123 | biostudies-literature
Unknown Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
| S-EPMC8450892 | biostudies-literature
Unknown Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
| S-EPMC10535083 | biostudies-literature
Unknown Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
| S-EPMC10476837 | biostudies-literature
Unknown Balancing effectiveness, toxicity, and individualization: enfortumab vedotin in advanced urothelial cancer.
| S-EPMC11986542 | biostudies-literature
Unknown Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.
| S-EPMC12530469 | biostudies-literature
Unknown Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma.
| S-EPMC8796084 | biostudies-literature
Unknown Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.
| S-EPMC11860999 | biostudies-literature